2-oxo-1-propan-2-yl-3H-benzimidazole-4-carbothioamide | 1283176-67-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-oxo-1-propan-2-yl-3H-benzimidazole-4-carbothioamide
• CAS: 1283176-67-9
• 化学式: C₁₁H₁₃N₃OS
• 分子量: 235.31
• InChiKey: HXRNEZKGPSYWFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  90.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-Bromo-2-methylnon-8-en-3-one 、 2-oxo-1-propan-2-yl-3H-benzimidazole-4-carbothioamide 以 乙醇 为溶剂， 反应 6.0h， 以13%的产率得到7-(5-pent-4-enyl-4-propan-2-yl-1,3-thiazol-2-yl)-3-propan-2-yl-1H-benzimidazol-2-one
  参考文献：
  名称：

  [EN] NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION
  [FR] NOUVEAUX INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'HÉPATITE C

  摘要：

  该发明涉及用于治疗丙型肝炎病毒的式I的大环化合物（其中变量如本文所定义）。还公开了与之相关的治疗方法、药物和剂型。

  公开号：

  WO2012037259A1

文献信息

• NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
  申请人：BUCKMAN Brad

  公开号：US20120101032A1

  公开（公告）日：2012-04-26

  The embodiments provide compounds of the general Formulae I, Ia, II, IIa, III, IIIa, IV, IVa, V, Va, VI and VIa, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  本实施例提供了一般式I、Ia、II、IIa、III、IIIa、IV、IVa、V、Va、VI和VIa的化合物，以及包括药物组成物在内的组合物，其中包括一种主体化合物。本实施例还提供了治疗方法，包括治疗丙型肝炎病毒感染和治疗肝纤维化的方法，该方法通常涉及向需要治疗的个体施用一种主体化合物或组合物的有效量。
• NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION
  申请人：Buckman Brad

  公开号：US20120094897A1

  公开（公告）日：2012-04-19

  The embodiments provide compounds of the general Formulae I, and II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  本实施例提供了一般式I和II的化合物，以及包括药物组合物在内的组合物。本实施例还提供了治疗方法，包括治疗丙型肝炎病毒感染和治疗肝纤维化的方法，通常涉及向需要的个体施用所述化合物或组合物的有效量的方法。
• [EN] CYCLIC PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION<br/>[FR] INHIBITEURS PEPTIQUES CYCLIQUES DE LA RÉPLICATION DU VIRUS DE L'HÉPATITE C
  申请人：INTERMUNE INC

  公开号：WO2011038293A1

  公开（公告）日：2011-03-31

  The embodiments provide compounds of the general Formulae I, Ia, II, III, IV, V, VI-1, VI-2, VII, VIII, IX, X, XI, and XII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
• [EN] THERAPEUTIC ANTIVIRAL PEPTIDES<br/>[FR] PEPTIDES ANTIVIRAUX THÉRAPEUTIQUES
  申请人：INTERMUNE INC

  公开号：WO2012047764A1

  公开（公告）日：2012-04-12

  The invention relates to compounds of Formula (I) (in which the variables are defined as herein) and compositions, including pharmaceutical compositions, thereof. The invention further provides treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis through administering to an individual in need thereof an effective amount of a subject compound or composition.
• [EN] NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION<br/>[FR] NOUVEAUX INHIBITEURS MACROCYCLIQUES DE LA RÉPLICATION DU VIRUS DE L'HÉPATITE C
  申请人：INTERMUNE INC

  公开号：WO2012054874A1

  公开（公告）日：2012-04-26

  The embodiments provide compounds of the general Formulae I, la, II, Ila, IIΙ, IIIa, IV, IVa, V, Va, VI and VIa, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.